Never miss a trade again with the fastest news alerts in the world!
 This headline only article is a sample of real-time intelligence
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Benzinga Pro</a> traders use to win in the markets everyday.
 Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters?
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Join 10,000+ serious traders in the Benzinga Pro community!</a>

Biotech

General

Assembly Biosciences Reports Interim Phase 1b Results From Trial Evaluating ABI-4334 In Chronic Hepatitis B; Says ABI-4334 Was Well Tolerated And Showed Mean Reduction Of 2.9 log IU/mL In Plasma HBV DNA Over 28 Days Of Treatment - Assembly Biosciences (NASDAQ:ASMB)

Benzinga Newsdesk

Assembly Biosciences

ASMB

Assembly Biosciences Reports Interim Phase 1b Results From Trial Evaluating ABI-4334 In Chronic Hepatitis B; Says ABI-4334 Was Well Tolerated And Showed Mean Reduction Of 2.9 log IU/mL In Plasma HBV DNA Over 28 Days Of Treatment

Comments